Abstract | PURPOSE: PATIENTS AND METHODS: Sixty-five patients with metastatic melanoma were enrolled. Treatment consisted of intravenous docetaxel (80 mg/m(2)) on day 1 and oral temozolomide (150 mg/m(2)) on days 1 to 5, every 4 weeks, for a maximum of six cycles. RESULTS: Sixty-two patients were eligible for the efficacy and safety analysis. Seventeen patients (27%) achieved an objective response, including five complete (8%) and 12 partial responses (19%). Median response duration was 9.5 months. Among responders, median time to progression ( TTP) was 11.2 months and median overall survival (OS) was 16 months. For all treated patients, the median TTP was 4 months and median OS was 11 months. Three (38%) of eight patients who presented with brain metastases had a partial response for 5, 6, and 12 months. Of 52 patients who did not have brain involvement at presentation, only four (8%) developed brain metastases at a median follow-up of 14 months. Myelosuppression was the primary toxicity. CONCLUSION:
|
Authors | D Bafaloukos, H Gogas, V Georgoulias, E Briassoulis, G Fountzilas, E Samantas, Ch Kalofonos, D Skarlos, A Karabelis, P Kosmidis |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 20
Issue 2
Pg. 420-5
(Jan 15 2002)
ISSN: 0732-183X [Print] United States |
PMID | 11786569
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study)
|
Chemical References |
- Taxoids
- Docetaxel
- Dacarbazine
- Paclitaxel
- Temozolomide
|
Topics |
- Administration, Oral
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects, therapeutic use)
- Brain Neoplasms
(secondary)
- Dacarbazine
(administration & dosage, analogs & derivatives)
- Disease-Free Survival
- Docetaxel
- Female
- Humans
- Infusions, Intravenous
- Male
- Melanoma
(drug therapy, pathology)
- Middle Aged
- Neutropenia
(chemically induced)
- Paclitaxel
(administration & dosage, analogs & derivatives)
- Skin Neoplasms
(drug therapy, pathology)
- Taxoids
- Temozolomide
- Thrombocytopenia
(chemically induced)
|